1. Home
  2. ASTH vs PHVS Comparison

ASTH vs PHVS Comparison

Compare ASTH & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Astrana Health Inc.

ASTH

Astrana Health Inc.

HOLD

Current Price

$37.66

Market Cap

1.9B

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$30.01

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASTH
PHVS
Founded
1994
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.8B
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
ASTH
PHVS
Price
$37.66
$30.01
Analyst Decision
Strong Buy
Buy
Analyst Count
7
11
Target Price
$34.86
$41.82
AVG Volume (30 Days)
410.9K
355.8K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.29
N/A
Revenue
$519,907,752.00
N/A
Revenue This Year
$27.38
N/A
Revenue Next Year
$10.78
N/A
P/E Ratio
$132.17
N/A
Revenue Growth
45.90
N/A
52 Week Low
$18.08
$15.93
52 Week High
$39.93
$33.33

Technical Indicators

Market Signals
Indicator
ASTH
PHVS
Relative Strength Index (RSI) 58.29 51.94
Support Level $36.95 $24.73
Resistance Level $39.93 $31.14
Average True Range (ATR) 1.48 1.47
MACD -0.44 -0.13
Stochastic Oscillator 28.39 32.80

Price Performance

Historical Comparison
ASTH
PHVS

About ASTH Astrana Health Inc.

Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: